Retargeting of T‐cell‐receptor gamma/delta+ lymphocytes against tumor cells by bispecific monoclonal antibodies. Induction of cytolytic activity and lymphokine production

Silvano Ferrini, Ignazia Prigione, Serafina Mammoliti, Maria Ines Colnaghi, Sylvie Menard, Alessandro Moretta, Lorenzo Moretta

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

We have recently selected MAbs specific for different molecular forms of the TCR gamma/delta (expressed by distinct cell subsets), able to activate TCR gamma/delta+ cells. Two of these reagents (Gl and A13) were used for the construction of bispecific MAbs in conjunction with a MAb (Mov 19) directed to ovarian carcinoma cells, using the hybrid hybridoma technique. The Gl‐derived bispecific MAb GM33.9 efficiently induced lysis of Mov19 ovarian carcinoma cell lines (IGROV1 and SW626) by Gl+ clones in a 4‐hr 51Cr‐release assay. On the other hand, it was ineffective when Mov19 target cells were used. Comparable results were obtained with the A13‐derived AM18.4 bispecific MAb when A13+ clones were used as effector cells. Bispecific MAbs were also able to induce secretion of IL‐2 and TNF‐alpha by TCR gamma/delta+ clones when Mov19+ target cells were present.

Original languageEnglish
Pages (from-to)53-55
Number of pages3
JournalInternational Journal of Cancer
Volume44
Issue number1 S
DOIs
Publication statusPublished - 1989

Fingerprint

Bispecific Antibodies
Lymphokines
Lymphocytes
Clone Cells
Neoplasms
Carcinoma
Somatostatin-Secreting Cells
Hybrid Cells
Hybridomas
Interleukin-2
Tumor Necrosis Factor-alpha
Cell Line

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Cancer Research

Cite this

@article{c9d85901039b4f2d98e8352c3d7a56f4,
title = "Retargeting of T‐cell‐receptor gamma/delta+ lymphocytes against tumor cells by bispecific monoclonal antibodies. Induction of cytolytic activity and lymphokine production",
abstract = "We have recently selected MAbs specific for different molecular forms of the TCR gamma/delta (expressed by distinct cell subsets), able to activate TCR gamma/delta+ cells. Two of these reagents (Gl and A13) were used for the construction of bispecific MAbs in conjunction with a MAb (Mov 19) directed to ovarian carcinoma cells, using the hybrid hybridoma technique. The Gl‐derived bispecific MAb GM33.9 efficiently induced lysis of Mov19 ovarian carcinoma cell lines (IGROV1 and SW626) by Gl+ clones in a 4‐hr 51Cr‐release assay. On the other hand, it was ineffective when Mov19− target cells were used. Comparable results were obtained with the A13‐derived AM18.4 bispecific MAb when A13+ clones were used as effector cells. Bispecific MAbs were also able to induce secretion of IL‐2 and TNF‐alpha by TCR gamma/delta+ clones when Mov19+ target cells were present.",
author = "Silvano Ferrini and Ignazia Prigione and Serafina Mammoliti and Colnaghi, {Maria Ines} and Sylvie Menard and Alessandro Moretta and Lorenzo Moretta",
year = "1989",
doi = "10.1002/ijc.2910440714",
language = "English",
volume = "44",
pages = "53--55",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "1 S",

}

TY - JOUR

T1 - Retargeting of T‐cell‐receptor gamma/delta+ lymphocytes against tumor cells by bispecific monoclonal antibodies. Induction of cytolytic activity and lymphokine production

AU - Ferrini, Silvano

AU - Prigione, Ignazia

AU - Mammoliti, Serafina

AU - Colnaghi, Maria Ines

AU - Menard, Sylvie

AU - Moretta, Alessandro

AU - Moretta, Lorenzo

PY - 1989

Y1 - 1989

N2 - We have recently selected MAbs specific for different molecular forms of the TCR gamma/delta (expressed by distinct cell subsets), able to activate TCR gamma/delta+ cells. Two of these reagents (Gl and A13) were used for the construction of bispecific MAbs in conjunction with a MAb (Mov 19) directed to ovarian carcinoma cells, using the hybrid hybridoma technique. The Gl‐derived bispecific MAb GM33.9 efficiently induced lysis of Mov19 ovarian carcinoma cell lines (IGROV1 and SW626) by Gl+ clones in a 4‐hr 51Cr‐release assay. On the other hand, it was ineffective when Mov19− target cells were used. Comparable results were obtained with the A13‐derived AM18.4 bispecific MAb when A13+ clones were used as effector cells. Bispecific MAbs were also able to induce secretion of IL‐2 and TNF‐alpha by TCR gamma/delta+ clones when Mov19+ target cells were present.

AB - We have recently selected MAbs specific for different molecular forms of the TCR gamma/delta (expressed by distinct cell subsets), able to activate TCR gamma/delta+ cells. Two of these reagents (Gl and A13) were used for the construction of bispecific MAbs in conjunction with a MAb (Mov 19) directed to ovarian carcinoma cells, using the hybrid hybridoma technique. The Gl‐derived bispecific MAb GM33.9 efficiently induced lysis of Mov19 ovarian carcinoma cell lines (IGROV1 and SW626) by Gl+ clones in a 4‐hr 51Cr‐release assay. On the other hand, it was ineffective when Mov19− target cells were used. Comparable results were obtained with the A13‐derived AM18.4 bispecific MAb when A13+ clones were used as effector cells. Bispecific MAbs were also able to induce secretion of IL‐2 and TNF‐alpha by TCR gamma/delta+ clones when Mov19+ target cells were present.

UR - http://www.scopus.com/inward/record.url?scp=84991125005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991125005&partnerID=8YFLogxK

U2 - 10.1002/ijc.2910440714

DO - 10.1002/ijc.2910440714

M3 - Article

VL - 44

SP - 53

EP - 55

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 1 S

ER -